Literature DB >> 12632507

A mutation specific polymerase chain reaction for detecting hepatitis B virus genome mutations at nt551.

Chun-Ling Ma1, De-Xing Fang, Hua-Biao Chen, Fa-Qing Li, Hui-Ying Jin, Su-Qin Li, Wei-Guo Tan.   

Abstract

AIM: The hepatitis B surface antigen (HBsAg) is considered to be one of the best markers for the diagnosis of acute and chronic HBV infection. But in some patients, this antigen cannot be detected by routine serological assays despite the presence of virus. One of the most important explanations for the lack of detectable HBsAg is that mutations which occur within the "a" determinant of HBV S gene can alter expression of HBsAg and lead to changes of antigenicity and immunogenicity of HBsAg accordingly. As a result, these mutants cannot be detected by diagnosis assays. Thus, it is essential to find out specific and sensitive methods to test the new mutants and further investigate their distribution. This study is to establish a method to investigate the distribution of the HBsAg mutant at nt551.
METHODS: A mutation specific polymerase chain reaction (msPCR) was established for amplifying HBV DNA with a mutation at nt551. Four sets of primer pairs, P551A-PPS, P551G-PPS, P551C-PPS and P551T-PPS, with the same sequences except for one base at 3' terminus were designed and synthesized according to the known HBV genome sequences and the popular HBV subtypes, adr and adw, in China. At the basis of regular PCR method, we explored the specific conditions for amplifying HBV DNAs with a mutation at nt551 by regulating annealing temperature and the concentration of these primers. 126 serum samples from patients of hepatitis B were collected, among which 16 were positive for HBV S DNA in the nested PCR amplification. These 16 HBV S DNAs were detected by using the msPCR method.
RESULTS: When the annealing temperature was raised to 71 degrees, nt551A and nt551G were amplified specifically by P551A-PPS and P551G-PPS; At 72 degrees and 5 pmole of the primers (each) in reaction of 25 microl volume, nt551C and nt551T were amplified specifically by P551C-PPS and P551T-PPS. 16 of HBV S gene fragments were characterized by using this method. 14 of them were positive for nt551A, one was positive for nt551G, and the other one was positive for nt551T. The results were confirmed by nucleotide sequencing.
CONCLUSION: The mutation specific polymerase chain reaction is a specific and sensitive method for detecting the mutations of HBV genome at nt551.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12632507      PMCID: PMC4621571          DOI: 10.3748/wjg.v9.i3.509

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  36 in total

1.  Immunoassay detection of hepatitis B surface antigen mutants.

Authors:  P F Coleman; Y C Chen; I K Mushahwar
Journal:  J Med Virol       Date:  1999-09       Impact factor: 2.327

2.  Horizontal transmission of a hepatitis B virus surface antigen mutant.

Authors:  W N Chen; C J Oon; S Koh
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

3.  Characterization of the reactivity pattern of murine monoclonal antibodies against wild-type hepatitis B surface antigen to G145R and other naturally occurring "a" loop escape mutations.

Authors:  M P Cooreman; M H van Roosmalen; R te Morsche; C M Sünnen; E M de Ven; J B Jansen; G N Tytgat; P L de Wit; W P Paulij
Journal:  Hepatology       Date:  1999-11       Impact factor: 17.425

4.  Comparing the immunogenicity of hepatitis B virus S gene variants by DNA immunization.

Authors:  L Wu; Z H Yuan; F Liu; J A Waters; Y M Wen
Journal:  Viral Immunol       Date:  2001       Impact factor: 2.257

Review 5.  Mutant hepatitis B viruses: a matter of academic interest only or a problem with far-reaching implications?

Authors:  G François; M Kew; P Van Damme; M J Mphahlele; A Meheus
Journal:  Vaccine       Date:  2001-07-16       Impact factor: 3.641

6.  Isolation, characterization and biological significance of hepatitis B virus mutants from serum of a patient with immunologically negative HBV infection.

Authors:  M Schories; T Peters; J Rasenack
Journal:  J Hepatol       Date:  2000-11       Impact factor: 25.083

7.  Unusual hepatitis B surface antigen variation in a child immunised against hepatitis B.

Authors:  L Roznovsky; T J Harrison; Z L Fang; R Ling; I Lochman; I Orsagova; L Pliskova
Journal:  J Med Virol       Date:  2000-05       Impact factor: 2.327

8.  Genetic alterations in the S gene of hepatitis B virus in patients with acute hepatitis B, chronic hepatitis B and hepatitis B liver cirrhosis before and after liver transplantation.

Authors:  F Rodriguez-Frias; M Buti; R Jardi; V Vargas; J Quer; M Cotrina; M Martell; R Esteban; J Guardia
Journal:  Liver       Date:  1999-06

9.  Molecular, immunological and clinical properties of mutated hepatitis B viruses.

Authors:  C Kreutz
Journal:  J Cell Mol Med       Date:  2002 Jan-Mar       Impact factor: 5.310

10.  Hepatitis B envelope protein mutants in human hepatocellular carcinoma tissues.

Authors:  S Zhong; J Y Chan; W Yeo; J S Tam; P J Johnson
Journal:  J Viral Hepat       Date:  1999-05       Impact factor: 3.728

View more
  1 in total

1.  Novel assay of competitively differentiated polymerase chain reaction for screening point mutation of hepatitis B virus.

Authors:  Xiao-Mou Peng; Xue-Juan Chen; Jian-Guo Li; Lin Gu; Yang-Su Huang; Zhi-Liang Gao
Journal:  World J Gastroenterol       Date:  2003-08       Impact factor: 5.742

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.